PMC:7205724 / 127-413
Annnotations
LitCovid-PubTator
| Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
|---|---|---|---|---|---|
| 3 | 125-132 | Species | denotes | patient | Tax:9606 |
| 5 | 204-212 | Disease | denotes | COVID-19 | MESH:C000657245 |
LitCovid-PD-FMA-UBERON
| Id | Subject | Object | Predicate | Lexical cue | fma_id |
|---|---|---|---|---|---|
| T1 | 5-20 | Body_part | denotes | immunoglobulins | http://purl.org/sig/ont/fma/fma62871 |
LitCovid-PD-MONDO
| Id | Subject | Object | Predicate | Lexical cue | mondo_id |
|---|---|---|---|---|---|
| T2 | 204-212 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
LitCovid-PD-CHEBI
| Id | Subject | Object | Predicate | Lexical cue | chebi_id |
|---|---|---|---|---|---|
| T2 | 26-41 | Chemical | denotes | corticosteroids | http://purl.obolibrary.org/obo/CHEBI_50858 |
| T3 | 94-109 | Chemical | denotes | corticosteroids | http://purl.obolibrary.org/obo/CHEBI_50858 |
| T4 | 157-172 | Chemical | denotes | corticosteroids | http://purl.obolibrary.org/obo/CHEBI_50858 |
| T5 | 267-282 | Chemical | denotes | corticosteroids | http://purl.obolibrary.org/obo/CHEBI_50858 |
LitCovid-sample-MedDRA
| Id | Subject | Object | Predicate | Lexical cue | meddra_id |
|---|---|---|---|---|---|
| T1 | 5-20 | http://purl.bioontology.org/ontology/MEDDRA/10022891 | denotes | immunoglobulins | http://purl.bioontology.org/ontology/MEDDRA/10021496 |
LitCovid-sample-CHEBI
| Id | Subject | Object | Predicate | Lexical cue | chebi_id |
|---|---|---|---|---|---|
| T1 | 26-41 | Chemical | denotes | corticosteroids | http://purl.obolibrary.org/obo/CHEBI_50858 |
| T2 | 94-109 | Chemical | denotes | corticosteroids | http://purl.obolibrary.org/obo/CHEBI_50858 |
| T3 | 157-172 | Chemical | denotes | corticosteroids | http://purl.obolibrary.org/obo/CHEBI_50858 |
| T4 | 267-282 | Chemical | denotes | corticosteroids | http://purl.obolibrary.org/obo/CHEBI_50858 |
LitCovid-sample-PD-NCBITaxon
| Id | Subject | Object | Predicate | Lexical cue | ncbi_taxonomy_id |
|---|---|---|---|---|---|
| T2 | 204-212 | Species | denotes | COVID-19 | NCBItxid:2697049 |
LitCovid-sample-sentences
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T4 | 43-53 | Sentence | denotes | Highlights |
| T5 | 54-142 | Sentence | denotes | • IVIG, combined with moderate-dose of corticosteroids, might improve patient outcomes. |
| T6 | 143-213 | Sentence | denotes | • The use of corticosteroids might accelerate recovery from COVID-19. |
LitCovid-sample-Pubtator
| Id | Subject | Object | Predicate | Lexical cue | pubann:denotes |
|---|---|---|---|---|---|
| 3 | 125-132 | Species | denotes | patient | Tax:9606 |
| 5 | 204-212 | Disease | denotes | COVID-19 | MESH:C000657245 |
LitCovid-sample-Enju
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T18 | 3-4 | -COMMA- | denotes | , |
| T19 | 5-20 | NNS | denotes | immunoglobulins |
| T20 | 20-21 | -COMMA- | denotes | , |
| T21 | 22-25 | CC | denotes | and |
| T22 | 26-41 | NNS | denotes | corticosteroids |
| T23 | 43-53 | NNS | denotes | Highlights |
| T24 | 54-55 | IN | denotes | • |
| T25 | 57-61 | NNP | denotes | IVIG |
| T26 | 61-62 | -COMMA- | denotes | , |
| T27 | 63-71 | VBN | denotes | combined |
| T28 | 72-76 | IN | denotes | with |
| T29 | 77-90 | NN | denotes | moderate-dose |
| T30 | 91-93 | IN | denotes | of |
| T31 | 94-109 | NNS | denotes | corticosteroids |
| T32 | 109-110 | -COMMA- | denotes | , |
| T33 | 111-116 | MD | denotes | might |
| T34 | 117-124 | VB | denotes | improve |
| T35 | 125-132 | NN | denotes | patient |
| T36 | 133-141 | NNS | denotes | outcomes |
| T37 | 143-144 | PDT | denotes | • |
| T38 | 146-149 | DT | denotes | The |
| T39 | 150-153 | NN | denotes | use |
| T40 | 154-156 | IN | denotes | of |
| T41 | 157-172 | NNS | denotes | corticosteroids |
| T42 | 173-178 | MD | denotes | might |
| T43 | 179-189 | VB | denotes | accelerate |
| T44 | 190-198 | NN | denotes | recovery |
| T45 | 199-203 | IN | denotes | from |
| T46 | 204-212 | NN | denotes | COVID-19 |
| T47 | 214-215 | PDT | denotes | • |
| T48 | 217-219 | DT | denotes | No |
| T49 | 220-230 | VBN | denotes | controlled |
| T50 | 231-239 | JJ | denotes | clinical |
| T51 | 240-246 | NNS | denotes | trials |
| T52 | 247-252 | VBP | denotes | exist |
| T53 | 253-255 | IN | denotes | on |
| T54 | 256-259 | DT | denotes | the |
| T55 | 260-263 | NN | denotes | use |
| T56 | 264-266 | IN | denotes | of |
| T57 | 267-282 | NNS | denotes | corticosteroids |
| T58 | 283-286 | IN | denotes | for |
| R16 | T19 | T18 | arg2Of | immunoglobulins,"," |
| R17 | T21 | T20 | arg1Of | and,"," |
| R18 | T18 | T21 | arg1Of | ",",and |
| R19 | T22 | T21 | arg2Of | corticosteroids,and |
| R20 | T25 | T24 | arg1Of | IVIG,• |
| R21 | T25 | T26 | arg1Of | IVIG,"," |
| R22 | T25 | T27 | arg2Of | IVIG,combined |
| R23 | T27 | T28 | arg1Of | combined,with |
| R24 | T29 | T28 | arg2Of | moderate-dose,with |
| R25 | T29 | T30 | arg1Of | moderate-dose,of |
| R26 | T31 | T30 | arg2Of | corticosteroids,of |
| R27 | T34 | T32 | arg1Of | improve,"," |
| R28 | T25 | T33 | arg1Of | IVIG,might |
| R29 | T34 | T33 | arg2Of | improve,might |
| R30 | T25 | T34 | arg1Of | IVIG,improve |
| R31 | T36 | T34 | arg2Of | outcomes,improve |
| R32 | T36 | T35 | arg1Of | outcomes,patient |
| R33 | T39 | T37 | arg1Of | use,• |
| R34 | T39 | T38 | arg1Of | use,The |
| R35 | T39 | T40 | arg1Of | use,of |
| R36 | T41 | T40 | arg2Of | corticosteroids,of |
| R37 | T39 | T42 | arg1Of | use,might |
| R38 | T43 | T42 | arg2Of | accelerate,might |
| R39 | T39 | T43 | arg1Of | use,accelerate |
| R40 | T44 | T43 | arg2Of | recovery,accelerate |
| R41 | T44 | T45 | arg1Of | recovery,from |
| R42 | T46 | T45 | arg2Of | COVID-19,from |
| R43 | T51 | T47 | arg1Of | trials,• |
| R44 | T51 | T48 | arg1Of | trials,No |
| R45 | T51 | T49 | arg2Of | trials,controlled |
| R46 | T51 | T50 | arg1Of | trials,clinical |
| R47 | T51 | T52 | arg1Of | trials,exist |
| R48 | T52 | T53 | arg1Of | exist,on |
| R49 | T55 | T53 | arg2Of | use,on |
| R50 | T55 | T54 | arg1Of | use,the |
| R51 | T55 | T56 | arg1Of | use,of |
| R52 | T57 | T56 | arg2Of | corticosteroids,of |
| R53 | T55 | T58 | arg1Of | use,for |
LitCovid-sample-PD-FMA
| Id | Subject | Object | Predicate | Lexical cue | fma_id |
|---|---|---|---|---|---|
| T1 | 5-20 | Body_part | denotes | immunoglobulins | http://purl.org/sig/ont/fma/fma62871 |
LitCovid-sample-PD-MONDO
| Id | Subject | Object | Predicate | Lexical cue | mondo_id |
|---|---|---|---|---|---|
| T2 | 204-212 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
LitCovid-sentences
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T4 | 43-53 | Sentence | denotes | Highlights |
| T5 | 54-142 | Sentence | denotes | • IVIG, combined with moderate-dose of corticosteroids, might improve patient outcomes. |
| T6 | 143-213 | Sentence | denotes | • The use of corticosteroids might accelerate recovery from COVID-19. |